Stoke Therapeutics (STOK) Other Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 27.68% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 27.68% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, up 40.77% from the prior year.
• Other Accumulated Expenses climbed to $1.5 million in Q1 2026 per STOK's latest filing, from $1.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.1 million in Q1 2025 and bottomed at $426000.0 in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $753000.0 (2024), against an average of $899529.4.
• Biggest YoY gain for Other Accumulated Expenses was 1421.43% in 2022; the steepest drop was 55.15% in 2022.
• Year by year, Other Accumulated Expenses stood at $509000.0 in 2022, then soared by 68.37% to $857000.0 in 2023, then dropped by 12.14% to $753000.0 in 2024, then surged by 40.77% to $1.1 million in 2025, then surged by 41.51% to $1.5 million in 2026.
• Per Business Quant, the three latest STOK Other Accumulated Expenses figures stand at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $795000.0 (Q3 2025).